GT Metabolic Solutions

About GT Metabolic Solutions

GT Metabolic Solutions, founded in May 2020, is a medical device company focused on the bariatric, metabolic, and digestive surgery markets. The company was established by Thierry Thaure, a seasoned medtech entrepreneur, and Dr. Michel Gagner, a pioneering laparoscopic and bariatric surgeon. Thaure serves as the CEO, bringing over 35 years of experience in building companies with disruptive technologies, including the successful sale of Cephea Valve Technologies to Abbott. Dr. Gagner, the Chief Medical Officer, is renowned for inventing the Laparoscopic Sleeve Gastrectomy (LSG), a widely adopted procedure for obesity and type 2 diabetes. The company's intellectual property is built upon a portfolio of 18 patents initially developed by Dr. Gagner and acquired by the new entity.

The firm's core business revolves around developing and commercializing minimally invasive technologies for creating surgical anastomoses (connections between parts of the intestine). Its clients are surgeons and hospital centers specializing in bariatric and metabolic procedures. The business model centers on selling its proprietary MagDI™ System, a disposable device, to these healthcare providers. In July 2022, the company secured approximately $15 million in a Series A financing round to fund clinical trials. A subsequent Series B round in March 2024 raised an additional $20.3 million.

GT Metabolic's flagship product is the MagDI™ System, a magnetic compression anastomosis technology. This system facilitates a side-to-side duodeno-ileal anastomosis, a key component of certain weight-loss surgeries. The procedure involves delivering two linear magnets orogastrically, which are then positioned laparoscopically on either side of the intestinal tissue. These powerful magnets compress the tissue walls together, eventually forming a fused connection, or anastomosis, without the need for traditional cutting, suturing, or stapling. A significant benefit is that no foreign materials like staples are left behind permanently; the magnets detach after the anastomosis is formed and are naturally expelled from the body. This approach is designed to lower the risk of complications such as bleeding and leakage. The company has received De Novo marketing authorization and subsequent FDA clearances for its system, including different magnet sizes (40mm and 50mm) to accommodate a wider range of patients. The first procedures using the MagDI™ System in the U.S. were completed in late 2024, marking the company's transition to commercialization.